Advertisement

Journal of Maxillofacial and Oral Surgery

, Volume 18, Issue 1, pp 159–160 | Cite as

The Importance of Panitumumab in Radiotherapy Involving Head and Neck Region

  • Yasemin Benderli Cihan
Letter to the Editor

References

  1. 1.
    Françoso A, Simioni PU (2017) Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Des Devel Ther 11:177–184.  https://doi.org/10.2147/dddt.s119036 (eCollection 2017) CrossRefGoogle Scholar
  2. 2.
    Ferris RL, Geiger JL, Trivedi S, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, Clump DA, Bauman JE, Ohr JP, Gooding WE, Argiris A (2016) Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer. Ann Oncol 27(12):2257–2262.  https://doi.org/10.1093/annonc/mdw428 (Epub 2016 Oct 11) CrossRefGoogle Scholar
  3. 3.
    Patel SB, Gill D, Garrido-Laguna I (2016) Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. OncoTargets Ther 9:75–86CrossRefGoogle Scholar
  4. 4.
    Mesıa R, Henke M, Fortin A et al (2015) Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16(2):208–220CrossRefGoogle Scholar
  5. 5.
    Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G et al (2015) Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 16(2):221–232.  https://doi.org/10.1016/S1470-2045(14)71200-8 (Epub 2015 Jan 15) CrossRefGoogle Scholar
  6. 6.
    Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, FitzGerald TJ, Childs TJ, Montenegro A, O’Sullivan B, Parulekar WR (2016) Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: a randomized clinical trial. JAMA Oncol.  https://doi.org/10.1001/jamaoncol.2016.4510 (Epubahead of print) Google Scholar
  7. 7.
    Pajares B, Trigo JM, Toledo MD, Álvarez M, González-Hermoso C, Rueda A, Medina JA, de Luque V, Jerez JM, Alba E (2013) Differential out come of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC Cancer 18(13):26.  https://doi.org/10.1186/1471-2407-13-26 CrossRefGoogle Scholar

Copyright information

© The Association of Oral and Maxillofacial Surgeons of India 2018

Authors and Affiliations

  1. 1.Department of Radiation OncologyKayseri Education and Research HospitalKayseriTurkey

Personalised recommendations